¡Ya estamos en !
Descubre más
ZYNE
Zynerba Pharmaceuticals, Inc
Excluida de cotización
ZYNE dejó de cotizar en bolsa el 10 de octubre de 2023.
Acerca de: Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists of Zygel which is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Empleados: 27
Noticias
Positivo
Neutral
Negativo
Sentimiento
3 meses
Positivo
0%
Neutral
0%
Negativo
0%
No hemos recibido artículos de noticias recientes sobre ZYNE.
Gráficos de precios implementados con Lightweight Charts™